Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real World Effectiveness of Upadacitinib on Early and Sustained Pain Control in Radiographic Axial Spondylarthritis (UPSTAND)

Next Previous
X
Search
Trial Profile

Real World Effectiveness of Upadacitinib on Early and Sustained Pain Control in Radiographic Axial Spondylarthritis (UPSTAND)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Ankylosing spondylitis; Back pain
  • Focus Therapeutic Use
  • Acronyms UPSTAND
  • Sponsors AbbVie

    • Most Recent Events

    • 15 Jun 2024 Interim Results assessing effectiveness of upadacitinib in Patients with Axial Spondyloarthritis presented at the 25th Annual Congress of the European League Against Rheumatism
    • 11 Mar 2024 Planned End Date changed from 31 May 2025 to 31 Mar 2025.
    • 07 Mar 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top